Intravenous Furosemide for Acute Decompensated Congestive Heart Failure: What Is the Evidence?

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• International guidelines universally recommend intravenous (IV) furosemide over oral administration for acute decompensated congestive cardiac failure.
• This recommendation is widely adopted in clinical practice for managing heart failure exacerbations.

Purpose of the Study:

• To critically evaluate the evidence supporting the universal recommendation of IV furosemide in acute decompensated congestive cardiac failure.
• To propose the need for clinical trials investigating the efficacy of higher oral furosemide doses before transitioning to IV therapy.

Main Methods:

• Review of existing literature and clinical guidelines regarding furosemide administration in acute decompensated congestive cardiac failure.
• Analysis of the current evidence base to identify gaps and limitations in supporting the IV route preference.

Main Results:

• The current evidence does not robustly support the universal recommendation of IV furosemide over oral administration.
• A potential strategy of escalating oral furosemide doses prior to IV administration may be viable.

Conclusions:

• The established guideline recommendation for IV furosemide in acute decompensated congestive cardiac failure may not be evidence-based.
• Further research, including randomized controlled trials, is warranted to compare higher-dose oral furosemide strategies against standard IV treatment to optimize patient outcomes and healthcare resource utilization.